[The benefit of a coronary stent in the reduction of major cardiac complications in acute coronary syndromes]. / Beneficio del stent coronario en la reducción de complicaciones cardiacas mayores en síndromes coronarios agudos.

To assess the incidence of in-hospital major adverse cardiac events (MACE), we analyzed 694 procedures in 613 consecutive patients during one year period. Patient population included 550 (79.2%) patients with unstable angina, 43 (6.2%) with stable angina and 101 (14.5%) with acute myocardial infarction. Elective percutaneous transluminal coronary angioplasty (PTCA) was performed in 593 (85.4%) patients, rescue PTCA in 7 (1%), and primary PTCA in 94 (13.5%). Angiographic lesion morphology was as follows: type A 30%; type B 58%; type C 12%. We compared patient population who received stent with PTCA-balloon only. Technical success was 95% and clinical success was achieved in 80% of the cases. Overall mortality was 1% in the stent group and 3% in the conventional PTCA. The incidence of MACE was 4% and 15.1% in the stent and angioplasty balloon groups respectively. We found a dramatic impact on reduction of the incidence of acute complications in the groups with stenting for unstable angina (p = 0.0001) and acute myocardial infarction (p = 0.0001). The major clinical advantage of stenting over balloon angioplasty was a lower need for repeated procedures.

[Coronary stent in acute myocardial infarction]. / Stent coronario en el infarto agudo del miocardio.

UNLABELLED: From December 1995 to March 1997 fifty patients with acute myocardial infarction, had 57 stents implanted. Mean time since the beginning of symptoms to the procedure was 3.7 +/- 2.9 hours. Twenty-four stents were implanted "de novo", 17 for "sub-optimal" results, 5 for threatened closure and eleven for complex dissection. The arteries treated with stent were left anterior descending in 42%, right coronary in 42%, circumflex in 10%, vein grafts in 4%, intermedial branch in 1% and marginal obtuse branch in 1%. Stent used in most of the cases was AVE in 67% followed by Palmaz-Schatz, Wiktor, Crown, Gianturco-Roubin and Wallstent. Before procedure, coronary flow was TIMI 0 in 66% TIMI 1 in 10% and TIMI 2 in 24%. After procedure, TIMI 3 coronary flow was achieved in 92% of the arteries and other four had "no-reflow" phenomenon. Mean stenosis before procedure was 96% +/- 3.1 and after stenting was 1.76% +/- 2.6 with a stent/artery diameter rate of 1.01. Technical success was 100% and clinical success was achieved in 96% of the cases. Two cases were not successfully due to acute thrombotic closure in one patient and in another one because of cardiogenic shock after two days of a technical successful implantation of stent in LAD artery. There were not recurrent ischemic events (CABG, re-infarction or new coronary angioplasty procedure). Other two patients died for non-cardiac events (acute pancreatitis in one and by septic shock in other). At the time of discharge 96% of patients were treated with aspirin and ticlopidine. Major hematoma was evident in only one case. At a mean follow-up time of 5.6 months +/- 4.2 in 45 patients showed that 73% were in functional class I and none of them had re-infarction, death or needed a new revascularization. CONCLUSION: Stent implantation in acute myocardial infarction is feasible and safe procedure with a low rate of ischemic recurrent events.

[Coronary stents. Results during the hospitalization phase]. / Stent coronario. Resultados en fase hospitalaria.

UNLABELLED: Between October 1991 and August 1996 two-hundred coronary stents were implanted (s) in 166 patients (pts) (1.27 s/pt). One hundred thirty-five lesions "de novo" were approached with stent, 44 because of a sub-optimal result post-angioplasty, 15 for restenosis and 17 for dissection. In thirty-six patients the indication of stenting was stable angina, in 68 unstable angina, in 37 for angina after myocardial infarction, in 11 for asymptomatic ischemia after myocardial infarction and in 14 during an acute myocardial infarction. Mean stenosis before stent implantation in all cases was 85 +/- 15%. Type of lesion in seventy cases was A, in 112 was B and 29 was C. Stents used were AVE in 146 lesions, Palmaz-Schatz in 33, Wiktor in 23, Gianturco-Roubin in 8 and Wallstent in one case. Medical treatment in 140 pts. (84.3%) after stent implantation was only with aspirin and ticlopidine. Technical success in all patients was 98.6% (208/211 pts) and primary success was 94.6% (157-166 pts). Unsuccessful procedures were because of sub-acute occlusion in three patients (1.8%), death in 3 pts. (1.8%) and urgent CABG was necessary in one pt. (0.5%). Major hematoma was a complication in 5 pts (3%). Mean residual stenosis after stent implantation in all cases was 2.2%. CONCLUSION: Stent implantation in our laboratory is a very safe procedure with a high rate of primary success with lowest complications in a great population of unstable angina.

[Complex coronary angioplasty. Report of 3 cases]. / Angioplastía coronaria compleja. Informe de tres casos.

Although coronary angioplasty is currently applied to a wide variety of obstructive coronary artery lesions, its indications have been reduced to certain selected cases. We present three cases of complex coronary angioplasty: in the elderly patient, after bypass surgery, and multiple lesions in one vessel comment about different causes that justify its use. We conclude emphasizing that currently percutaneous coronary angioplasty is a secure and successful alternative of treatment even in complex cases, if they are properly selected.

[Control of oral anticoagulation. Current concepts]. / El control de la anticoagulación oral. Conceptos actuales.

The main objective of this short review is to bring into focus the most relevant of the recent advances in prothrombin time standardization and analyze the recommendations of the World Health Organization (WHO) for monitoring patients with thrombotic disorders under treatment with oral anticoagulant drugs. The prothrombin time (PT) is indicative of the proper therapeutic range in patients receiving oral anticoagulant drugs; however the reliability of the results will depend on the source and nature of the thromboplastin used. Different normal and therapeutic rangers are frequently observed when different brands of thromboplastin reagents and/or methods are used. The WHO, in conjunction with the International Committee of Thrombosis and Hemostasis and the International Committee of Standardization in Hematology, has recommended a calibration scheme for thromboplastin standardization with special reference for anticoagulant monitoring. Instead of reporting patient values, either in seconds or percent activity, WHO recommends the PT results in terms of an international normalized ratio (INR). This is obtained by formula: INR = RC in which R is the patient's PT and C is the international sensitivity index (ISI) of the thromboblastine employed. The INR represents the PT that would be obtained if it were performed with the WHO thromboplastin reference preparation. We suggest that these new concepts should be implemented by both laboratory and clinical professionals with the purpose of improving the effectiveness and safety of oral anticoagulation.